Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001031830 | SCV001195137 | pathogenic | Rubinstein-Taybi syndrome due to EP300 haploinsufficiency; Colorectal cancer | 2019-04-22 | criteria provided, single submitter | clinical testing | This variant is an out-of-frame deletion of the genomic region encompassing exons 15-16 of the EP300 gene. This is expected to create a premature translational stop signal and result in an absent or disrupted protein product. This variant has not been reported in the literature in individuals with EP300-related conditions. Loss-of-function variants in EP300 are known to be pathogenic (PMID: 15706485, 24476420). For these reasons, this variant has been classified as Pathogenic. |
Labcorp Genetics |
RCV003104007 | SCV001586929 | pathogenic | Rubinstein-Taybi syndrome due to EP300 haploinsufficiency | 2019-04-16 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in EP300 are known to be pathogenic (PMID: 15706485, 24476420). This variant has not been reported in the literature in individuals with EP300-related conditions. This variant is an out-of-frame deletion of the genomic region encompassing exons 15-16 of the EP300 gene. This is expected to create a premature translational stop signal and result in an absent or disrupted protein product. |